Study of a new drug for advanced solid tumors with MSI-H or dMMR
Treatments studied
Part of Cancer, Digestive system, Women’s health & pregnancy clinical trials.
This trial tests an oral medication called MOMA-341 in people with advanced solid tumors that have high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). It aims to see if the drug can help when prior immunotherapy hasn't worked or isn't available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have an advanced or metastatic solid tumor that is MSI-H or dMMR and has not responded to prior immunotherapy (or you were unable to get it).
- You have at least one tumor that can be seen on scans.
- You are able to perform daily activities with few or no limitations (ECOG performance status 0-2).
- You have recovered from side effects of previous treatments, and your organs are working well enough.
- You agree to use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug, M0324, alone or combined with pembrolizumab or chemotherapy, for advanced solid tumors that have a protein called MUC-1 on their surface. It may be an option for patients whose cancer has not responded to standard treatments.
This study tests a combination of two drugs (LM-108 and toripalimab) for people with advanced solid tumors that have a specific marker called MSI-H or dMMR. It is for those whose cancer has grown after previous immunotherapy treatment.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) for people with advanced gastric cancer that has a specific DNA repair problem (MSI-H/dMMR). It is for those who have not yet had any treatment for their advanced cancer.
This trial tests a new oral drug called ISM5939 for people with advanced solid tumors that haven't responded to or can't use standard treatments. The goal is to see if the drug is safe and works against the cancer.
This Phase 1/2 trial tests MHB036C in people with advanced or metastatic solid cancers that have stopped responding to standard treatments (or no standard options exist). It is meant to see how the drug works and how safe it is in this group.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.